Q2/H1 2023

Results

Presentation

July 25th 2023

DISCLAIMER

This presentation is intended to provide a general overview of The Navigator Company S.A.'s business and does not purport to deal with all aspects and details regarding The Navigator Company S.A..

This presentation has been prepared by The Navigator Company S.A. for information purposes only. Some statements in this presentation are forward-looking, based on assumptions and current expectations of future events. Although The Navigator Company, S.A. believes that these were reasonable when made, such statements are inherently subject to significant known and unknown risks and contingencies, which relate to factors that are beyond the ability of The Navigator Company, S.A. to control or estimate precisely, such as international economic conditions, foreign exchange fluctuations, credit markets, the cost of raw materials, legal and regulatory requirements, including measures adopted in connection with the prevention of the dissemination of SARS-CoV-2/COVID-19 and that could cause actual results to differ substantially from those expressed or implied by such statements.

Except as required by any applicable law or regulation, The Navigator Company S.A. or any of its affiliates, directors, officers, employees or advisers or any other person assumes no obligation whatsoever to update the information contained in this presentation or to notify a reader in the event that any matter stated herein changes or becomes inaccurate.

1

P A R T I C I P A T I O N<<

Executive Directors

Investor Relations

António Redondo

Dorival Almeida

Fernando Araújo

João Lé

Nuno Santos

Ana Canha

2

Q2/H1 2023 RESULTS

PRESENTATION

<<

0102 03

Main

Market &

Group

Outlook

Highlights

Performance

33

Q2/H1 2023 | SOLID RESULTS DESPITE

CHALLENGING MARKET CONDITIONS

  • Second best result for a first half: Extremely difficult market with pulp prices falling and UWF and Packaging market-driven weak apparent demand;
  • Tissue segment with strong demand for finished goods with price resilience and has successfully begun the process of Tissue Ejea integration;
  • Cash costs on a downward trend:
    • QoQ - Pulp and Paper cash costs down 9% to 12% and Tissue down 3%;
    • H1 23 vs H2 22 - Pulp and Paper average cash cost down 8% and 5% in Tissue.
  • EBITDA has reached € 253 million, margin of 25.8%, enabled by:
    • Product mix enrichment with paper and tissue prices still at high levels, and significant managed cash cost reduction;
  • Strong Capex plan - € 113 million in H1
  • Strong financial position - Net Debt/EBITDA ratio at 0.89x;
  • Sustainability commitment on all fronts

4

<<

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

The Navigator Company SA published this content on 26 July 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 July 2023 15:00:05 UTC.